McAbs has high targeting ability and can directly reach the diseased cells. Now McAbs are widely used in clinical practice with the unique advantages of reducing the damage of normal cells side effects. The market share monoclonal antibody in global biopharmaceuticals has increased from 10% in 2000 to 42% in 2016. It is the largest and fastest growing fine industry in the modern biopharmaceutical industry. According to Chlue Research, the total sales of 52 kinds of McAbs approved by FDA were up to 99 billion US dollars in 2016, up 15% from 2015. McAbs occupy six seats of the world's top ten best-selling drugs.